Impact of Pharmacist-Led Continuous Glucose Monitoring on Clinical Outcomes in People With Type 2 Diabetes in Primary Care: Protocol for a Prospective Cohort Study
JMIR Research Protocols · 2025
DOI: 10.2196/67014 ↗At a glance
Kohortenstudie in JMIR Research Protocols, 2025. Written by Kevin Cowart and 5 co-authors. Institution: Department of Pharmacotherapeutics & Clinical Research, Taneja College of Pharmacy, University of South Florida, Tampa, FL, United States. Major MEDLINE topics: Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Pharmacists. Cited 3 times so far (Crossref); 28 references. The full text is freely available in PubMed Central.
Topics: Diabetes mellitus
Abstract (original language)
Background
Continuous glucose monitoring (CGM) is increasingly being recognized as the new standard of care for glycemic monitoring in people with type 2 diabetes (T2D). However, despite advances in therapeutics and technology, glycemic control remains suboptimal. Team-based approaches involving pharmacists, particularly in primary care, have shown to be effective in addressing these shortcomings yet have not been rigorously evaluated in the literature.
Objective
Herein we present the protocol for a study that seeks to evaluate the change in hemoglobin A1c (HbA1c) in people with T2D using CGM under a pharmacist-led approach as compared with a pharmacist-led approach using no CGM (only self-monitoring blood glucose with a glucometer). We will also assess changes in CGM-derived glycemic outcomes, health behavior, and safety outcomes among the pharmacist-led CGM cohort.
Methods
This is a 12-week prospective cohort study in an academic family medicine department. We will enroll adults with T2D and a HbA1c level of ≥8%. Participants in the intervention cohort will wear a CGM sensor (FreeStyle Libre 2) for 12 weeks and receive structured diabetes self-management education and support from a pharmacist. Each participant in the intervention group will have 5 visits with a pharmacist. The primary objective is the between-group difference in change in HbA1c levels from baseline to 12 weeks between the intervention and historical cohort. Secondary objectives include a change in CGM-derived metrics among the intervention group from baseline to 12 weeks, and a change in health behavior via the Summary of Diabetes Self-Care Activities measure from baseline to 12 weeks in the intervention cohort. A CGM survey will also be administered to participants in the intervention cohort to evaluate changes in diet, physical activity, general lifestyle, and medication adherence. Safety endpoints will also be evaluated. The primary and secondary outcomes will be analyzed within and between groups using descriptive statistics, with a multivariable regression analysis conducted as appropriate to adjust for potential known confounding effects.
Results
This study was funded in July 2023. We began enrolling participants in December 2024. At the time of writing, 3 participants have been enrolled. It is anticipated that we will conclude this study in December 2025 and expect to disseminate results in March 2026.
Conclusions
Results of this study will further elucidate the role of pharmacist-led CGM in primary care. Trial Registration ClinicalTrials.gov NCT06572306; https://clinicaltrials.gov/study/NCT06572306 International Registered Report Identifier (IRRID) PRR1-10.2196/67014
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacotherapeutics & Clinical Research, Taneja College of Pharmacy, University of South Florida, Tampa, FL, United States.
- Department of Family Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
- College of Public Health, University of South Florida, Tampa, FL, United States.
- Department of Internal Medicine & Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
ORCID profiles: Kevin Cowart, Raechel T White, Kevin Olson, Nicholas W Carris, Karim Hanna, Janice Zgibor
Cite
APA
Cowart, K., White, R. T., Olson, K., Carris, N. W., Hanna, K., & Zgibor, J. (2025). Impact of Pharmacist-Led Continuous Glucose Monitoring on Clinical Outcomes in People With Type 2 Diabetes in Primary Care: Protocol for a Prospective Cohort Study. JMIR Research Protocols. https://doi.org/10.2196/67014
Vancouver
Cowart K, White RT, Olson K, Carris NW, Hanna K, Zgibor J. Impact of Pharmacist-Led Continuous Glucose Monitoring on Clinical Outcomes in People With Type 2 Diabetes in Primary Care: Protocol for a Prospective Cohort Study. JMIR Research Protocols. 2025. doi:10.2196/67014
BibTeX
@article{Cowart2025,
author = {Cowart, Kevin and White, Raechel T and Olson, Kevin and Carris, Nicholas W and Hanna, Karim and Zgibor, Janice},
title = {Impact of Pharmacist-Led Continuous Glucose Monitoring on Clinical Outcomes in People With Type 2 Diabetes in Primary Care: Protocol for a Prospective Cohort Study},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/67014}
}
EUVIMED